Zenatsehay Gebretsadik
Psychiatric/Mental Health · Columbia, MDNPI 1053087106
Payments from drug & device makers
Across 762 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- plus $7K from 24 others
What the payments were for
- Food & beverage$14,40199%
- Education$1511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 105 | $1,552 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 66 | $1,488 |
| AbbVie | 87 | $1,400 |
| Alkermes, Inc. | 79 | $1,227 |
| Teva Pharmaceuticals USA, Inc. | 59 | $1,171 |
| Neurocrine Biosciences, Inc. | 49 | $1,126 |
| Axsome Therapeutics, Inc. | 37 | $913 |
| Otsuka America Pharmaceutical, Inc. | 41 | $804 |
| Neos Therapeutics, LP | 33 | $671 |
| Corium, LLC | 28 | $639 |
| Vanda Pharmaceuticals Inc. | 17 | $441 |
| Johnson & Johnson | 15 | $414 |
| Supernus Pharmaceuticals, Inc. | 24 | $322 |
| Sunovion Pharmaceuticals Inc. | 16 | $300 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $245 |
| E.r. Squibb & Sons, L.L.C. | 11 | $223 |
| Idorsia Pharmaceuticals US Inc | 11 | $205 |
| Ironshore Pharmaceuticals Inc. | 9 | $204 |
| Boston Scientific | 3 | $161 |
| Tris Pharma Inc | 9 | $160 |
| Bausch Health US, LLC | 11 | $153 |
| Merck | 10 | $148 |
| Almatica Pharma LLC | 6 | $143 |
| Avanir Pharmaceuticals, Inc. | 8 | $117 |
| Noven Therapeutics, LLC | 5 | $79 |
| Neuronetics, Inc. | 3 | $78 |
| Collegium Pharmaceutical, Inc. | 3 | $59 |
| Indivior Inc. | 2 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,552 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 26 | $77,347 |
| VraylarCariprazine Hcl | 18 | $26,421 |
| Aripiprazole | 80 | $10,172 |
| XanaxAlprazolam | 11 | $8,565 |
| Quetiapine Fumarate | 111 | $6,674 |
| Ziprasidone Hcl | 12 | $5,059 |
| Bupropion XlBupropion Hcl | 102 | $4,376 |
| Escitalopram Oxalate | 168 | $3,276 |
| Clozapine | 26 | $2,293 |
| Duloxetine Hcl | 90 | $2,056 |
| Trazodone Hcl | 160 | $1,663 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 27 | $1,628 |
| Olanzapine | 39 | $1,432 |
| Sertraline Hcl | 48 | $1,209 |
| Lamotrigine | 85 | $1,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $804 | $77,34726 claims |
| AbbVieVraylar | $1,400 | $26,42118 claims |
| Almatica Pharma LLCSertraline Hcl | $143 | $1,20948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Other psychiatric/mental health in Columbia
- Michelle WilliamsColumbia$158K
- Elshaday TeferiColumbia$11K
- Benjamin DahunsiColumbia$5K
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Kristin ClemensGaithersburg$36K
- Antonio HeroldHavre de Grace$23K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.